Investors

We are transforming the science of medical imaging, creating a new world of possibilities for the biopharmaceutical industry and healthcare professionals alike. By accelerating the development of new therapies and improving the diagnosis and treatment of serious diseases, we deliver value for our investors and partners, as well as those whose lives we touch.

We deliver on a global scale. Our reach stretches worldwide, from the USA, the world’s largest healthcare market, across Europe, and into Asia, an increasingly important region for clinical development and patient care. This global presence is reflected by our work with world-leading pharmaceutical and biotechnology companies and contract research organizations. The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Learn about our technology
Read about our capabilities

Message from the CEO

Board of directors and management team

Experienced leadership

Median’s management team has extensive experience of the imaging, patient care and clinical trial sectors. Our Board of Directors brings significant industry, financial and strategic expertise to the company.

Board of directors

Management team

Major shareholders

Stock market data

Median Technologies is listed on Euronext Growth

(ISIN: FR0011049824, ticker: ALMDT)

Share price data

View price chart

Stock market data

Place of listing

Euronext Growth

Number of shares

12,127,425
(May 30, 2020)

Share code

Name
Median Technologies

Mnemonic
ALMDT

ISIN Code
FR0011049824

Shareholding structure (June 20, 2020)

Non-nominative information as of June 19, 2020

FURUI Medical Science Company Luxembourg: 12.4%
Celestial Successor Fund LP: 10.8%
Abingworth LLP -nominative and non nominative-: 9.2%
Canon Inc: 7.9%
Growth equity opportunities fund III LLC managed by NEA: 7.9%

Funds managed by Idinvest Partners -nominative and non nominative-: 6.1%
Auriga Ventures II -nominative and non nominative-: 5.4%
Founders: 7.2%
Others: 33.1%

Financial agenda

2020
- Publication of our half-year results 2020: after the close of trading on October 14, 2020
- Publication of our annual results 2019: after the close of trading on April 14, 2020
2019
- Publication of our half-year results 2019: after the close of trading on October 3, 2019
- Publication of our annual results for 2018: after the close of trading on April 11, 2019
2018
- Publication of our half-year results 2018: after the close of trading on October 11, 2018
- Publication of our annual results for 2017: after the close of trading on April 12, 2018
2017
- Publication of our half-year results 2017: after the close of trading on October 10, 2017
- Publication of our annual results for 2016: after the close of trading on April 12, 2017
2016
- Publication of our half-year results 2016: after the close of trading on October 12, 2016
- Publication of our annual results for 2015: after the close of trading on April 12, 2016

2015
- Publication of our half-year results 2015: after the close of trading on October 5, 2015
- Publication of our annual results for 2014: after the close of trading on April 15, 2015
2014
- Publication of our half-year results 2014: after the close of trading on October 9, 2014
- Publication of our annual results for 2013: after the close of trading on April 28, 2014
2013
- Publication of our half-year results 2013: after the close of trading on October 10, 2013
- Publication of our annual results for 2012: after the close of trading on April 10, 2013
2012
- Publication of our half-year results 2012: after the close of trading on October 8, 2012
- Publication of our annual results for 2011: after the close of trading on February 16, 2012
2011
- Publication of our half-year results 2011: after the close of trading on September 16, 2011